U.S. markets closed
  • S&P Futures

    4,128.00
    +3.50 (+0.08%)
     
  • Dow Futures

    32,764.00
    +27.00 (+0.08%)
     
  • Nasdaq Futures

    13,048.25
    +16.75 (+0.13%)
     
  • Russell 2000 Futures

    1,915.50
    +0.90 (+0.05%)
     
  • Crude Oil

    90.48
    -0.02 (-0.02%)
     
  • Gold

    1,810.50
    -1.80 (-0.10%)
     
  • Silver

    20.50
    +0.01 (+0.06%)
     
  • EUR/USD

    1.0208
    -0.0009 (-0.09%)
     
  • 10-Yr Bond

    2.7970
    +0.0320 (+1.16%)
     
  • Vix

    21.77
    +0.48 (+2.25%)
     
  • GBP/USD

    1.2073
    -0.0003 (-0.03%)
     
  • USD/JPY

    135.1440
    +0.0280 (+0.02%)
     
  • BTC-USD

    23,122.48
    -698.07 (-2.93%)
     
  • CMC Crypto 200

    537.58
    -19.77 (-3.55%)
     
  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     
  • Nikkei 225

    27,999.96
    0.00 (0.00%)
     

Why Are Karyopharm Shares Plunging Today?

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Karyopharm Therapeutics Inc (NASDAQ: KPTI) revealed that executive vice president and chief medical officer Jatin Shah departs for "other professional opportunities."

  • While CEO Paulson looks for Shah's replacement, he has recruited two Big Pharma vets to take up key posts on the team:

    • Patricia Judson, who led women's oncology at GlaxoSmithKline and AstraZeneca, will become the SVP of medical strategy.

    • From AbbVie, Amgen, and Eli Lilly, Stuart Poulton has been appointed SVP of strategy and portfolio management.

  • Karyopharm unveiled Phase 3 results for Xpovio in endometrial cancer, noting the drug cut the risk of disease progression or death by 30% compared to placebo, with median progression-free survival coming in at 5.7 months for the active arm and 3.8 months for the placebo cohort.

  • Price Action: KPTI shares are down 26.80% at $10.52 during the market session on the last check Tuesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.